Claims for Patent: 8,440,703

Summary for Patent: 8,440,703

Title:	Methods of using sustained release aminopyridine compositions
Abstract:	A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Inventor(s):	Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee:	Acorda Therapeutics, Inc. (Ardsley, NY)
Application Number:	13/299,969
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,440,703
Patent Claims:	1. A method of improving lower extremity function in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of less than 15 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein the amount of said 4-aminopyridine administered to said patient in each said administering step is the same over said time period. 2. A method of improving lower extremity function in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks. 3. The method of claim 1, wherein the improving lower extremity function in the patient is increasing walking speed of the patient. 4. The method of claim 1, wherein the lower extremity function is lower extremity muscle strength. 5. The method of claim 1, wherein the lower extremity function is lower extremity muscle tone. 6. The method of claim 1, wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient. 7. The method of claim 2, wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient. 8. The method of claim 1, wherein twice daily is about every 12 hours. 9. The method of claim 2, wherein twice daily is about every 12 hours. 10. The method of claim 1, wherein said sustained release composition is a tablet. 11. The method of claim 2, wherein said sustained release composition is a tablet. 12. The method of claim 8, wherein said sustained release composition is a tablet. 13. The method of claim 9, wherein said sustained release composition is a tablet. 14. The method of claim 1, wherein said sustained release composition provides a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml. 15. The method of claim 2, wherein said sustained release composition provides a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml. 16. The method of claim 1, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 6 hours after administration of the sustained release composition to the patient. 17. The method of claim 2, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 6 hours after administration of the sustained release composition to the patient. 18. The method of claim 1, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient. 19. The method of claim 2, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient. 20. The method of claim 1, wherein said sustained release composition is capable of providing, upon administration to the patient, a release profile of the 4-aminopyridine extending over at least 6 hours. 21. The method of claim 2, wherein said sustained release composition is capable of providing, upon administration to the patient, a release profile of the 4-aminopyridine extending over at least 6 hours. 22. The method of claim 1, wherein said 4-aminopyridine is dispersed in a rate of release controlling polymer. 23. The method of claim 2, wherein said 4-aminopyridine is dispersed in a rate of release controlling polymer. 24. The method of claim 1, wherein said sustained release composition comprises a matrix, in which said 4-aminopyridine is uniformly dispersed, that is suitable for controlling the release rate of the 4-aminopyridine. 25. The method of claim 2, wherein said sustained release composition comprises a matrix, in which said 4-aminopyridine is uniformly dispersed, that is suitable for controlling the release rate of the 4-aminopyridine. 26. The method of claim 1, wherein said patient has relapsing remitting multiple sclerosis. 27. The method of claim 2, wherein said patient has relapsing remitting multiple sclerosis. 28. The method of claim 1, wherein said time period is more than two weeks. 29. The method of claim 2, wherein said time period is more than two weeks. 30. The method of claim 1, wherein said time period comprises twelve weeks. 31. The method of claim 2, wherein said time period comprises twelve weeks. 32. The method of claim 1, wherein the lower extremity function is walking. 33. The method of claim 32, wherein said method comprises initiating treatment of said patient with 4-aminopyridine by orally administering said sustained release composition twice daily to said patient. 34. The method of claim 32, wherein said sustained release composition is a tablet, and wherein twice daily is about every 12 hours. 35. The method of claim 32, wherein said sustained release composition provides a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml. 36. The method of claim 2, wherein the lower extremity function is walking, and wherein said sustained release composition provides a release profile to obtain a C.sub.avSS of about 15 ng/ml to about 35 ng/ml. 37. The method of claim 32, wherein said sustained release composition provides a mean .sub.Tmax in a range of about 2 to about 6 hours after administration of the sustained release composition to the patient. 38. The method of claim 2, wherein the lower extremity function is walking, and wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 6 hours after administration of the sustained release composition to the patient. 39. The method of claim 32, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient. 40. The method of claim 34, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient. 41. The method of claim 2, wherein the lower extremity function is walking, and wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient. 42. The method of claim 32, wherein said sustained release composition comprises a matrix, in which said 4-aminopyridine is uniformly dispersed, that is suitable for controlling the release rate of the 4-aminopyridine. 43. The method of claim 2, wherein the lower extremity function is walking, and wherein said sustained release composition comprises a matrix, in which said 4-aminopyridine is uniformly dispersed, that is suitable for controlling the release rate of the 4-aminopyridine. 44. The method of claim 32, wherein said time period is more than two weeks. 45. The method of claim 2, wherein the lower extremity function is walking, and wherein said time period is more than two weeks. 46. The method of claim 32, wherein said time period comprises twelve weeks. 47. The method of claim 40, wherein the lower extremity function is walking, and wherein said time period comprises twelve weeks. 48. The method of claim 32, wherein said sustained release composition is capable of providing, upon administration to the patient, a release profile of the 4-aminopyridine extending over at least 6 hours. 49. The method of claim 2, wherein the lower extremity function is walking, and wherein said sustained release composition is capable of providing, upon administration to the patient, a release profile of the 4-aminopyridine extending over at least 6 hours. 50. The method of claim 32, wherein said 4-aminopyridine is dispersed in a rate of release controlling polymer. 51. The method of claim 2, wherein the lower extremity function is walking, and wherein said 4-aminopyridine is dispersed in a rate of release controlling polymer. 52. The method of claim 32, wherein said patient has relapsing remitting multiple sclerosis.